Aiden has first worked on simulations during studying statistics to understand which sample sizes lead to sufficient performance of statistics, which are only asymptotically normal. It helped him in many situations, in which it was difficult to tackle a problem analytically. Simulations help us understand very complex situations, and the development of new treatments is surely a very complex topic.
He has invested an enormous amount of time to leverage simulations for understanding the designs of studies and development programs.
In this episode, I discuss the following questions with him:
- Why is trial simulation necessary?
- What design features do you assess?
- How do you get a good stability in terms of the simulation precision?
- Where are the limitations to these simulations?
- What are his experiences in communicating the outcomes of the simulation?
- How he thinks simulating studies or development programs will look like in 5 years?
Listen to this episode while we answer these six important questions.
Reference:
https://exploristics.com/kerus-cloud/keruscloud2
Listen and share this episode with your friends and colleagues!
Never miss an episode!
Join thousends of your peers and subscribe to get our latest updates by email!
Get the
Learn on demand
Click on the button to see our Teachble Inc. cources.
Featured courses
Click on the button to see our Teachble Inc. cources.
Aiden Flynn, BSc MSc PhD
Chief Executive Officer
Aiden is the founder of Exploristics and has over 20 years’ experience in the life sciences sector. After seven years as a researcher and lecturer at University College London, Aiden spent ten years at GlaxoSmithKline as a director of statistical support for biomarker studies across research and development. Here, he was responsible for developing and implementing the pharmacogenetics strategy that enabled the use of genetic data in clinical studies. This involved the integration of a wide range of capabilities across R&D such as new analysis tools and methods, bioinformatics, data standards, processes and training.
In recent years, Aiden has worked closely with regulatory authorities, such as the FDA and EMA, to develop tools and guidelines that support the use of biomarkers in clinical studies. Since founding Exploristics in 2009, Aiden has overseen its growth, creating an innovative and profitable company able to cater to a wide range of healthcare developers from the world’s top pharmaceutical companies to biotechnology, medical device and diagnostic start-ups.
Join The Effective Statistician LinkedIn group
This group was set up to help each other to become more effective statisticians. We’ll run challenges in this group, e.g. around writing abstracts for conferences or other projects. I’ll also post into this group further content.
I want to help the community of statisticians, data scientists, programmers and other quantitative scientists to be more influential, innovative, and effective. I believe that as a community we can help our research, our regulatory and payer systems, and ultimately physicians and patients take better decisions based on better evidence.
I work to achieve a future in which everyone can access the right evidence in the right format at the right time to make sound decisions.
When my kids are sick, I want to have good evidence to discuss with the physician about the different therapy choices.
When my mother is sick, I want her to understand the evidence and being able to understand it.
When I get sick, I want to find evidence that I can trust and that helps me to have meaningful discussions with my healthcare professionals.
I want to live in a world, where the media reports correctly about medical evidence and in which society distinguishes between fake evidence and real evidence.
Let’s work together to achieve this.
